IOVA - Iovance Biotherapeutics, Inc.
| Previous close | 8.22 |
| Open | 8.15 |
| Bid | 8.10 x 3200 |
| Ask | 8.11 x 2200 |
| Day's range | 8.08 - 8.32 |
| 52-week range | 5.28 - 13.44 |
| Volume | |
| Avg. volume | 4,801,107 |
| Market cap | 1.833B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.40 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.38 |
Motley FoolWhy Shares of Iovance Biotherapeutics Jumped Tuesday
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up more than 17% late Tuesday afternoon after the clinical-stage biotech company announced that the Food and Drug Administration (FDA) had approved its biologics license application (BLA) for lifileucel, as a combination therapy with Merck's Keytruda (pembrolizumab) to treat advanced melanoma. Iovance specializes in using tumor-infiltrating lymphocytes as therapies to fight cancer cells. Iovance announced on late Friday that the FDA had granted lifileucel Priority Review status and set a Prescription Drug User Fee Act (PDUFA) date of Nov. 25 for the cell therapy.
ZacksFDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
ZacksIovance (IOVA) Posts Narrower-Than-Expected Loss in Q1
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.
Motley FoolWhy Shares of Iovance Biotherapeutics Jumped Monday
What happened Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up by more than 14% late Monday afternoon. There were two factors that brought the clinical-stage biotech company's shares up Monday.
Motley FoolWall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
After a dreadful 2022, growth stocks have started to rebound in 2023. The tech-heavy Nasdaq Composite has gained a healthy 15.4% so far this year. For example, Wall Street analysts think small-cap biotechs Iovance Biotherapeutics (NASDAQ: IOVA) and Seres Therapeutics (NASDAQ: MCRB) could see a parabolic rise in their respective share prices in 2023.
ZacksWhy Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
- Zacks
Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil
Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.
ZacksDrug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More
Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.
ZacksIovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%
Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.
Motley FoolWhy Iovance Biotherapeutics Stock Soared 12% Higher Today
Investors were more than cheered by a business update from cancer-focused biotech Iovance Biotherapeutics (NASDAQ: IOVA) on Monday. For Proleukin, an interleukin-2 molecule used to stimulate T-cell activity in the fight against cancer, Iovance is making an upfront payment of 166.7 million British pounds ($206.6 million). It is also on the hook for a 41.7 million pound ($51.7 million) milestone payment upon first approval of its leading pipeline therapy, advanced melanoma treatment Lifileucel, and what it described only as double-digit worldwide sales royalties derived from Proleukin.
- Zacks
Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
Motley FoolWhy Iovance Biotherapeutics Is Crashing Today
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.
- Zacks
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
ZacksIovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
- Zacks
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
- Zacks
Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.
- Zacks
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
- Zacks
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.